AstraZeneca Shares: NYSE Listing and EU Approval Recommendation Boost Outlook

AstraZeneca (LON: AZN) is poised for increased investor attention as it commences trading on the New York Stock Exchange (NYSE) today, February 2, 2026.

Simultaneously, the European Medicines Agency's CHMP recommended approval of Imfinzi in combination with FLOT chemotherapy for early-stage gastric and gastroesophageal junction cancers.

These developments signal a potentially significant period of growth and expansion for the pharmaceutical giant.

The move to list ordinary shares on the NYSE harmonizes AstraZeneca's global listing structure across New York, London, and Stockholm.

This broadened accessibility to the U.S. capital market could attract a wider investor base, potentially driving increased trading volume and share value. Michel Demaré, Chair of AstraZeneca, stated this move “gives broader access to the largest capital market in the world,” opening opportunities for more investors to participate in the company's future.

The CHMP's positive opinion for Imfinzi stems from the MATTERHORN Phase III trial, which demonstrated a 29% reduction in the risk of disease progression, recurrence, or death compared to chemotherapy alone.

The trial also showed a 22% reduction in the risk of death. These results highlight the potential of Imfinzi to become a new standard of care for patients with these cancers in the EU.

Headline Numbers:

• Event-Free Survival (EFS): 29% reduction in risk of progression, recurrence, or death compared to chemotherapy alone.
• Overall Survival (OS): 22% reduction in the risk of death compared to chemotherapy alone.
• 3-Year Survival Rate: 69% for the Imfinzi regimen versus 62% for chemotherapy alone.

These figures highlight a substantial improvement in patient outcomes, suggesting a strong market opportunity for Imfinzi within the early gastric cancer treatment landscape.

Driver Breakdown:

• NYSE Listing: Increased access to U.S. investors and capital markets.
• Imfinzi Approval: Expansion of Imfinzi's therapeutic applications and market reach.
• Strong Pipeline: Potential for future revenue growth driven by new drug launches.

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said, “Imfinzi plus FLOT demonstrated a durable, increasing long-term survival benefit in the MATTERHORN trial, with more than two-thirds of patients alive at three years.”